Friday, April 24, 2015 1:12:23 AM
"Ask About CINV" Campaign Highlights Gap in Perception of CINV Between Patients and Health Care Providers and the Importance of Encouraging Patients to Talk About Their Symptoms
WALTHAM, Mass., April 23, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the launch of Ask About CINV ( http://www.askaboutcinv.com/ ) , a campaign to raise awareness of chemotherapy-induced nausea and vomiting (CINV) and the importance of fostering an open dialogue about CINV among patients and their health care providers. The campaign features several patients living with cancer who have experienced firsthand the detrimental impact of CINV and are sharing their stories to help others. This campaign was unveiled today at the Oncology Nursing Society 40th Annual Congress in Orlando, Florida.
"It's important to raise awareness of nausea and vomiting before the start of chemotherapy so that patients are encouraged to ask their health care team about how best to prevent it," said Lonnie Moulder, CEO of TESARO. "By preventing CINV, healthcare providers can help patients focus on other essential aspects of their cancer treatment."
If not prevented, more than half of patients who undergo chemotherapy will experience severe nausea following chemotherapy administration, and more than 30 percent will go on to experience vomiting. Yet research suggests that physicians and nurses may underestimate the incidence of nausea and vomiting, particularly in the days following chemotherapy administration. In one study, greater than 75% of physicians and nurses underestimated the incidence of delayed nausea and vomiting following chemotherapy1.This significant gap between perception and patient experience is due in part to the fact that patients often experience their symptoms outside of the clinic and may not report them to their healthcare provider.
"Many patients don't report their experience with nausea and vomiting because they expect it to be an unavoidable side effect of chemotherapy," said Rebecca Clark Snow, RN, BSN, OCN. "But this does not need to be the case. As nurses, we can be significant advocates for our patients throughout their cancer treatment journey, particularly through education. It is important that we encourage patients to keep the lines of communication open during treatment so that we have an accurate understanding of antiemetic efficacy. Our goal should be prevention of CINV for all patients prior to the initiation of chemotherapy."
To learn more, please visit www.askaboutCINV.com ( http://www.askaboutcinv.com/ ) or visit booth 1445 at the Oncology Nursing Society 40th Annual Congress from April 23rd through 26th.
About Chemotherapy-Induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) can affect up to 90 percent of patients receiving chemotherapy without appropriate prevention and can lead to dehydration, weight loss, malnutrition, hospitalization and delays in or even discontinuation of treatment.
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com ( http://www.tesarobio.com/ ) .
¹Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: Perception vs. Reality. Grunberg, et al. Cancer. V100, Issue 10, May 2004.
CONTACT: Investor/Media Contact:
Jennifer Davis
Sr. Director, Corporate Development & Investor Relations
+1.781.325.1116 or jdavis@tesarobio.com ( mailto:davis@tesarobio.com )
Recent OPK News
- OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development • GlobeNewswire Inc. • 09/23/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2024 06:56:10 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/18/2024 08:13:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 09:00:42 PM
- Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health • PR Newswire (US) • 09/16/2024 11:30:00 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/30/2024 09:01:33 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/23/2024 09:33:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 09:23:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:50:25 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/12/2024 10:27:05 PM
- Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/09/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 09:39:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:12:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:07:42 PM
- OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 08/07/2024 08:06:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:21:51 PM
- OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 09:03:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:49:22 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/26/2024 11:43:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:18:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:11:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:08:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:05:39 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM